Potential blockbuster asthma drug met goals in trials, GSK says

By Steve Goldstein

Asthma drug could generate more than GBP3 billion of annual sales, GSK has previously estimated

GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than GBP3 billion ($3.8 billion) met their goals.

GSK (GSK) (UK:GSK) said both trials of depemokimab reduced the annualized rate of asthma attacks over 52 weeks. The drug targets an inflammation that is the underlying pathology responsible for 80% of people with severe asthma.

GSK said the full results will be presented at an upcoming scientific congress and will be used to support regulatory submissions worldwide.

U.S.-listed GSK shares, up 20% this year, were steady in early trade.

The company previously called GlaxoSmithKline has said it plans to submit the drug for approval in the second half of the year.

In a company presentation in January, GSK said depemokimab could have peak annual sales of more than GBP3 billion, citing a more potent pharmacology, a longer half-life and and a twice-yearly dosing interval.

Analysts at Barclays estimate peak sales of GBP1 billion.

Discussing first-quarter results, Luke Miels, GSK's chief commercial officer, said the enthusiasm toward the drug stems from knowing patients would prefer something twice a year versus up to 26 times.

-Steve Goldstein

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-21-24 0948ET

Copyright (c) 2024 Dow Jones & Company, Inc.